Navigation Links
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
Date:9/12/2011

LISBON, Portugal, Sept. 12, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON™ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients receiving BYDUREON for the treatment of type 2 diabetes experienced improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels. These findings will be presented at the 47th European Association for the Study of Diabetes Annual Meeting in Lisbon, Portugal.

"Patients with diabetes are at least twice as likely as people without the disease to have heart disease or a stroke. Having other chronic conditions including obesity, high blood pressure or high cholesterol further increases this risk," said James Malone, MD, global exenatide medical director, Lilly Diabetes. "These data underscore the need to consider not only glycemic control but also the important role played by other medical conditions that are common among patients with type 2 diabetes."

Study Results: Patients participating in the DURATION-3 study received BYDUREON or Lantus® (insulin glargine) in addition to metformin or metformin plus a sulfonylurea. Interim results from the study's ongoing extension found that patients receiving BYDUREON and completing 84 weeks of therapy:

  • Demonstrated statistically significant reduction in body weight (
    '/>"/>

  • SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
    2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
    3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
    4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
    5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
    6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
    7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
    8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
    9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
    10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
    11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
    (Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
    (Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
    Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
    ... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
    ... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
    Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
    (Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
    (Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
    (Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
    (Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
    (Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
    Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
    ... A recent study estimates that nearly 30,000 men will ... study offers hope for these patients: // The combination ... improves survival rates. ,AST inhibits the release of ... three years of AST with radiation therapy has been ...
    ... compression stockings can reduce complications after a blood clot ... uncomfortable .// ,Some of the common complications with ... leg include swelling, skin discoloration, numbness, chronic pain, hardening ... suggested that elastic stockings could help patients with blood ...
    ... of people worldwide . It is the most common form ... are still unknown and there is no cure. ,New ... to treating Alzheimer’s disease. A team of researchers tested ... were given sage oil capsules, and some were given placebos. ...
    ... to researchers a group of cells, called satellite cells, ... older people maintain // their youthfulness. These cells rescue ... They also generate new cells for future repairs. Previous ... protein called Notch is activated by another protein called ...
    ... Chronic obstructive pulmonary disease, an often neglected disease of the ... The vast majority of people with the disease are smokers. ... from wood fires also comes into play in some cases. ... in fact, it will be the third leading cause of ...
    ... news for the many adults and children who have endured ... ,Developing a vaccine to prevent group A streptococcal infections has ... years. Group A streptococcus is responsible for a variety of ... most common. ,The vaccine trial included 28 adults ...
    Cached Medicine News:
    The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
    ...
    ...
    ... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
    Medicine Products: